First Breakthrough Therapy Designation for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan
Based on TROPION-Lung05 Phase II trial and supported by data from TROPION-Lung01 Phase III trial
https://www.businesswire.com/news/home/20241209094703/en/
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.